Phibro Animal Health Corporation (NASDAQ:PAHC) Given Consensus Rating of “Hold” by Analysts

Phibro Animal Health Corporation (NASDAQ:PAHC) has been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $37.50.

PAHC has been the subject of a number of analyst reports. JPMorgan Chase & Co. increased their price target on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,040 shares of Phibro Animal Health stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00. Following the sale, the chief executive officer directly owned 36,680 shares in the company, valued at approximately $1,885,352. This trade represents a 16.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 293,920 shares of company stock worth $13,833,025 over the last three months. Company insiders own 50.13% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Phibro Animal Health by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after buying an additional 13,884 shares during the last quarter. State Street Corp raised its position in Phibro Animal Health by 5.4% in the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after acquiring an additional 48,243 shares during the period. Millennium Management LLC boosted its stake in Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares during the last quarter. Geode Capital Management LLC boosted its stake in Phibro Animal Health by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after acquiring an additional 21,951 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after acquiring an additional 6,826 shares during the period. 99.34% of the stock is currently owned by institutional investors.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Zacks added PAHC to multiple Rank #1 (Strong Buy) lists — including momentum and value screens — which can attract short-term momentum traders and systematic buy programs. Best Momentum Stocks to Buy for February 20th New Strong Buy Stocks for February 20th Best Value Stocks to Buy for February 20th
• Positive Sentiment: Analyst models moved higher: Zacks Research has repeatedly raised quarterly and full‑year EPS forecasts (FY2026 to $2.96 from $2.73 and upgrades to FY2027/FY2028 estimates), signaling improved earnings visibility after the company’s February quarter beat and FY2026 guidance. That fundamental re-rating supports higher multiples. MarketBeat PAHC coverage
• Positive Sentiment: Recent fundamentals: Phibro beat Q4/quarterly estimates and gave FY2026 EPS guidance (2.93–3.10), and it declared a modest quarterly dividend — all supportive to investor confidence and institutional interest. MarketBeat PAHC coverage
• Neutral Sentiment: A Yahoo Finance piece flags valuation after the recent run — helpful context for investors assessing whether current gains are driven by fundamentals or short‑term momentum. It suggests caution on stretch valuations even as momentum persists. Assessing Phibro Animal Health (PAHC) Valuation After Strong Share Price Momentum
• Neutral Sentiment: Analyst mix remains mixed: despite estimate lifts, coverage is varied (several Holds, a few Buys and one Sell per MarketBeat), so upside depends on continued execution vs. elevated expectations. MarketBeat PAHC coverage
• Negative Sentiment: Insider selling: CEO Jack Bendheim has sold multiple sizable blocks in February (recent disclosures show several transactions at ~\$51–\$52), which some investors view as a negative signal on near‑term insider conviction. That selling can cap enthusiasm despite the other positives. Phibro Animal Health (NASDAQ:PAHC) CEO Sells $361,856.00 in Stock

Phibro Animal Health Trading Up 1.8%

PAHC opened at $52.80 on Friday. Phibro Animal Health has a fifty-two week low of $16.16 and a fifty-two week high of $56.30. The firm has a market capitalization of $2.14 billion, a PE ratio of 23.47, a P/E/G ratio of 0.80 and a beta of 0.80. The company has a debt-to-equity ratio of 2.14, a current ratio of 3.05 and a quick ratio of 1.22. The company’s 50-day moving average is $42.44 and its 200 day moving average is $39.95.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, research analysts predict that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio is currently 21.33%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.